While cancer vaccines seem straightforward in theory, numerous vaccines have shown promise in early phases of development only to have difficulties meeting endpoints in Phase III clinical trials. At this time, only one true cancer vaccine has been approved by the FDA; Sipuleucel-T (Provenge®) which is used to treat advanced prostate cancer.

Despite these shortcomings, many pharmaceutical companies have become increasingly invested in cancer immunotherapies. Currently, there are over 100 immunotherapy products in various stages of development, and many are specific active immunotherapies (vaccines) that have already entered into clinical development and several are currently in or have recently completed Phase III trials.

The discovery of several tumor-associated antigens is raising hopes for developers of cancer vaccines. As envisioned by researchers, cancer vaccines hold the potential to be specific, safe, and long-lasting while eliciting minimal associated toxicity.

As a follow-up our The High Stakes Of Running A Successful Oncology Trial featured in Life Science Leader last year, Clinipace Worldwide is currently working on another article looking at different facets of cancer vaccine development, including clinical research and studies, regulatory aspects, the clinical operations side, and technology’s role in running a vaccine trial.

We’ll also highlight some of our clients working in this space to gain some additional insight and industry perspective from the trenches.